Novo Nordisk's deal with Korro is worth a total of $530 million in research and development (R&D) funding, milestone payments ...

RBC Capital analyst Luca Issi maintained a Buy rating on Korro Bio (KRRO – Research Report) today and set a price target of $95.00. The ...

Novo Nordisk isn’t done with the RNA deals, this time penning a $530 million biobucks deal to work with Korro Bio on two ...

Analyst Kostas Biliouris from BMO Capital maintained a Buy rating on Korro Bio (KRRO – Research Report) and keeping the price target at ...

Gene Editing Korro Bio's Preclinical Data 'Best-In-Class', Analyst Initiates With Outperform Rating William Blair initiates coverage on Korro Bio highlighting its innovative RNA editing platform ...

Cambridge, USA-based Korro Bio has entered a collaboration with Denmark’s Novo Nordisk to advance the discovery and ...

Korro Bio Inc. has established a collaboration with Novo Nordisk A/S to advance the discovery and development of new genetic medicines, initially to treat cardiometabolic diseases. The collaboration ...

CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA ...

CAMBRIDGE, Mass., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA ...

On Thursday, BMO Capital Markets maintained its Outperform rating on shares of Korro Bio Inc. (NASDAQ:KRRO) with a steady price target of $120.00. The firm highlighted the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...